Because the different causes of Imprime-mediated immune activation are fundamental to priming a de novo T cell response as well as enhancing existing T cell immunity, we next investigated whether Imprime treatment could activate CD8 T cell responses using the well-studied chicken OVA antigen model antigen as well as the MC38 tumor model. This evidence concerns the gene CD8A and neoplasm.